{"schema_version":"1.0","type":"article","title":"Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors","url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata-en.md","lang":"en","date":"2026-08-02","publish_at":"2026-08-02T08:00:00+08:00","updated_at":"2026-08-02","category":"商業分析系列","topic":"商業分析系列","tags":["alopecia areata","bempikibart","Q32 Bio","QTTB","IL-7Rα","JAK inhibitors","SALT","biotech valuation","clinical data","drug development"],"summary":"Q32 Bio nearly doubled after a 33-patient, single-arm Phase 2a readout. The investable questions are whether efficacy survives randomization, whether responses persist after treatment stops, and whether a larger safety database can support a differentiated place beside JAK inhibitors.","key_points":[],"facts":[],"sections":["01 | First, understand what SALT measures","02 | Forty percent is striking, but the denominator was 25","03 | Why a non-JAK mechanism excited the market","04 | “Hair keeps growing after treatment stops” remains a question","05 | After the stock nearly doubled, the real test begins","06 | The next competitive round in alopecia areata","07 | Industry coordinates for Taiwan investors","08 | Conclusion: separate “worth validating” from “already proven”","References","Disclaimer"],"references":[{"title":"The following are primary sources or official trial records. Verification cutoff: July 19, 2026.","source":"","date":"","url":""},{"title":"Q32 Bio, SIGNAL-AA Part B Week 36 topline results:","source":"","date":"","url":"https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-positive-36-week-topline-results-part-b-signal"},{"title":"ClinicalTrials.gov, SIGNAL-AA (NCT06018428):","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06018428"},{"title":"Q32 Bio, pricing of the $200 million public offering:","source":"","date":"","url":"https://ir.q32bio.com/news-releases/news-release-details/q32-bio-announces-pricing-200-million-public-offering-common/"},{"title":"Q32 Bio SEC filing:","source":"","date":"","url":"https://ir.q32bio.com/node/10981/html"},{"title":"AbbVie, FDA submission for upadacitinib in severe alopecia areata:","source":"","date":"","url":"https://news.abbvie.com/2026-04-28-AbbVie-Submits-Application-to-FDA-for-Upadacitinib-RINVOQ-R-for-Adults-and-Adolescents-with-Severe-Alopecia-Areata"},{"title":"Nektar, 52-week REZOLVE-AA results and development stage:","source":"","date":"","url":"https://ir.nektar.com/news-releases/news-release-details/52-week-topline-results-16-week-blinded-treatment-extension"},{"title":"Nasdaq, QTTB historical prices:","source":"","date":"","url":"https://www.nasdaq.com/market-activity/stocks/qttb/historical"}],"images":[{"alt":"A 33-patient trial nearly doubled Q32 Bio shares, but the evidence remains an early Phase 2a signal","url":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/figure-01.png"},{"alt":"The same 10 responders yield different percentages when the denominator changes from 25 to 33","url":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/figure-02.png"},{"alt":"A clean 33-patient safety signal cannot exclude low-frequency risks that emerge with larger exposure","url":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/figure-03.png"},{"alt":"The next bempikibart test is Week 52 durability, controlled replication and larger safety exposure","url":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-02）。Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors。https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-08-02-bempikibart-alopecia-areata.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}